HKSE - Delayed Quote HKD

Abbisko Cayman Limited (2256.HK)

7.830

+0.130

+(1.69%)

At close: May 9 at 4:08:05 PM GMT+8

2025 AACR | Abbisko Therapeutics Presents Late-Breaking Pre-clinical Research Results on ABSK112 (EGFR exon20ins), ABSK131 (PRMT5*MTA), and ABK-KRAS-1

Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics 02256.HK) today announced that it has presented four late-breaking pre-clinical research posters at the 2025 AACR conference held in Chicago, Illinois (USA) from April 25 to April 30. Results were shared for ABSK112 (EGFR exon20ins inhibitor), ABSK131 (PRMT5*MTA inhibitor), and ABK-KRAS-1 (pan-KRAS inhibitor), as well as results from a study investigating potential resistance mechanisms to KRAS G12C inhibitors.

PR Newswire 12 days ago

2256.HK
+1.69%
Merck Exercised the Option for the Global Rights of Abbisko Therapeutics's Pimicotinib

On April 1, 2025, Beijing Time, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fee of USD85.0 million, under the licensing agreement signed in December 2023. The development represents further deepening of the collaboration, underscoring the unwavering commitment and confidence that both parties possess for the ongoing advancement of pimicotinib.

PR Newswire last month

2256.HK
+1.69%
Serko And 2 Other Promising Penny Stocks To Watch

Global markets have been buoyed by optimism surrounding potential trade deals and enthusiasm for artificial intelligence, with major U.S. indices reaching record highs. Amid these developments, investors are increasingly seeking stocks that combine growth potential with financial stability. Penny stocks, often associated with smaller or newer companies, offer such opportunities at lower price points. Despite being a somewhat outdated term, penny stocks remain relevant as they can present...

Simply Wall St. 3 months ago

2256.HK
+1.69%

COBJF

SERKF
Discover Anora Group Oyj And Two Other Promising Penny Stocks

As global markets navigate recent fluctuations, highlighted by a cautious Federal Reserve and political uncertainties, investors are exploring diverse opportunities to balance risk and reward. Penny stocks, often representing smaller or newer companies, remain an intriguing area for those seeking potential growth beyond the well-trodden paths of larger indices. Despite being considered an outdated term by some, penny stocks can still offer value through affordability and growth potential when...

Simply Wall St. 4 months ago

2256.HK
+1.69%

ANORA.HE
2024 ASH Oral Presentation----Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting

December 8, 2024, Abbisko Therapeutics (HKEX: 02256) announced the presentation of preliminary Phase 2 study results for pimicotinib (ABSK021) in patients with chronic Graft-versus-Host Disease (cGvHD) who have either progressed or not responded to one or more prior lines of therapy. The presentation took place at the 66th ASH Annual Conference, held December 7-10, 2024, in San Diego, California. Despite most enrolled patients having not yet completed the 6-month treatment cycle required for cGv

PR Newswire 4 months ago

2256.HK
+1.69%
November 2024's Top Penny Stocks To Watch

As global markets navigate the complexities of policy shifts and economic indicators, investors are keenly observing how these factors influence various sectors. In this context, penny stocks—often representing smaller or emerging companies—continue to capture interest due to their unique potential for growth and affordability. While the term may seem dated, it remains relevant as these stocks often offer intriguing opportunities when backed by strong financial fundamentals.

Simply Wall St. 5 months ago

2256.HK
+1.69%

YSASF
/C O R R E C T I O N -- Abbisko/

Abbisko today announced that the Phase 3 MANEUVER study evaluating pimicotinib in the treatment of tenosynovial giant cell tumor (TGCT) achieved statistically significant improvements in objective response rate (ORR) at Week 25 of 54.0%, compared with 3.2% for placebo (p< 0.0001) based on RECIST v1.1 per Blinded Independent Review Committee（BIRC）.

PR Newswire 5 months ago

2256.HK
+1.69%
3 Penny Stocks With Market Caps Larger Than US$300M To Watch

As global markets show varied performances, with small-cap indices like the Russell 2000 and S&P MidCap 400 outperforming their larger counterparts, investors are keenly observing opportunities across different market segments. Penny stocks, despite their somewhat outdated moniker, continue to attract attention as potential investment vehicles for those seeking value in smaller or newer companies. This article explores three penny stocks that stand out due to their financial robustness and...

Simply Wall St. 6 months ago

2256.HK
+1.69%
Best Poster of ESMO 2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC

Abbisko Therapeutics (HKEX: 02256) is excited to announce the receipt of the ESMO 2024 Best Poster Award on September 16, 2024. The award was received for the presentation titled "Updated Safety and Efficacy of Irpagratinib (ABSK011) in advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression from a Phase 1 study". The update data from ABSK-011-101 study showed a tolerable safety profile and promising anti-tumor activity of Irpagratinib monotherapy in aHCC. Of note, in aHCC patients wh

PR Newswire 7 months ago

2256.HK
+1.69%
Exploring iDreamSky Technology Holdings And Two Other Undervalued Small Caps With Insider Actions In Hong Kong

Amid a backdrop of global market fluctuations and specific downturns in Hong Kong's Hang Seng Index, investors might find potential opportunities in undervalued small-cap stocks. These smaller companies, often less scrutinized by mainstream analysts, can offer unique growth prospects especially when insider actions suggest confidence in the firm's future.

Simply Wall St. 10 months ago

2256.HK
+1.69%

1119.HK

1277.HK
50% ORR: Impressive Clinical Trial Data for Irpagratinib Combined with Atezolizumab in Advanced Hepatocellular Carcinoma Stuns ESMO-GI Congress

Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) announced that it has presented new phase II clinical data of its highly selective FGFR4 inhibitor irpagratinib (ABSK011) in combination with atezolizumab for the treatment of advanced hepatocellular carcinoma（HCC）at the 2024 ESMO-GI Congress. The presentation highlights that 220mg BID of irpagratinib in combination with atezolizumab demonstrated promising antitumor activity with an objective response rate (ORR) of 50% in FGF19+ HCC patients.

PR Newswire 10 months ago

2256.HK
+1.69%
Exploring Undervalued Small Caps With Insider Action In Hong Kong June 2024

In recent trading sessions, the Hong Kong market has shown resilience, with the Hang Seng Index gaining modestly amid mixed economic signals from China. This backdrop sets an intriguing stage for investors to explore undervalued small-cap stocks, particularly those with recent insider buying activity, which can be a positive signal about a stock's future prospects in current market conditions.

Simply Wall St. 10 months ago

1277.HK

1119.HK

2256.HK
+1.69%
Exploring Undervalued Small Caps With Insider Actions In Hong Kong June 2024

As of June 2024, the Hong Kong market is showing resilience with the Hang Seng Index posting a modest gain amidst mixed economic signals from mainland China. This context of fluctuating industrial outputs and retail sales growth provides a nuanced backdrop for investors looking at potential opportunities in undervalued small-cap stocks. In such an environment, identifying small-cap stocks that are potentially undervalued requires a keen understanding of market dynamics and insider actions,...

Simply Wall St. 10 months ago

GRDZF

FRTCF

2256.HK
+1.69%
Exploring Undervalued Small Caps With Insider Action In June 2024 in Hong Kong

As global markets navigate through a period of fluctuating inflation rates and interest rate expectations, the Hong Kong small-cap sector presents a unique landscape for investors seeking value. Amidst broader market dynamics, understanding the intrinsic qualities that define promising small-cap stocks—such as robust insider buying—can offer insightful perspectives in June 2024.

Simply Wall St. 10 months ago

FRTCF

NSFCF

2256.HK
+1.69%
Exploring Undervalued Small Caps With Insider Buying In Hong Kong June 2024

As of June 2024, the Hong Kong market reflects a cautious sentiment, mirroring broader global economic uncertainties and localized challenges. With the Hang Seng Index experiencing a notable decline, it becomes increasingly important to identify small-cap companies that demonstrate strong potential for value appreciation amidst prevailing market conditions. In this context, stocks with insider buying activity can signal robust future prospects as insiders often buy shares based on their confiden

Simply Wall St. 10 months ago

1119.HK

1475.HK

2256.HK
+1.69%

Performance Overview

Return	2256.HK	HANG SENG INDEX (^HSI)
YTD	+69.85%	+14.00%
1-Year	+123.71%	+23.36%
3-Year	+105.51%	+14.33%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Abbisko Cayman Limited (2256.HK)

2025 AACR | Abbisko Therapeutics Presents Late-Breaking Pre-clinical Research Results on ABSK112 (EGFR exon20ins), ABSK131 (PRMT5*MTA), and ABK-KRAS-1

Merck Exercised the Option for the Global Rights of Abbisko Therapeutics's Pimicotinib

Serko And 2 Other Promising Penny Stocks To Watch

Discover Anora Group Oyj And Two Other Promising Penny Stocks

2024 ASH Oral Presentation----Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting

November 2024's Top Penny Stocks To Watch

/C O R R E C T I O N -- Abbisko/

3 Penny Stocks With Market Caps Larger Than US$300M To Watch

Best Poster of ESMO 2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC

Exploring iDreamSky Technology Holdings And Two Other Undervalued Small Caps With Insider Actions In Hong Kong

50% ORR: Impressive Clinical Trial Data for Irpagratinib Combined with Atezolizumab in Advanced Hepatocellular Carcinoma Stuns ESMO-GI Congress

Exploring Undervalued Small Caps With Insider Action In Hong Kong June 2024

Exploring Undervalued Small Caps With Insider Actions In Hong Kong June 2024

Exploring Undervalued Small Caps With Insider Action In June 2024 in Hong Kong

Exploring Undervalued Small Caps With Insider Buying In Hong Kong June 2024

Performance Overview